EP Patent

EP4399203A1 — Chlorinated tetralin compounds and pharmaceutical compositions

Assigned to SpringWorks Therapeutics Inc · Expires 2024-07-17 · 2y expired

What this patent protects

The present disclosures are directed to chlorinated tetralin compounds and pharmaceutical compositions.

USPTO Abstract

The present disclosures are directed to chlorinated tetralin compounds and pharmaceutical compositions.

Drugs covered by this patent

nirogacestat-hydrobromide (NIROGACESTAT HYDROBROMIDE)

Patent Metadata

Patent number: EP4399203A1
Jurisdiction: EP
Classification: —
Expires: 2024-07-17
Drug substance claim: No
Drug product claim: No
Assignee: SpringWorks Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.